{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:09:46Z","timestamp":1776053386712,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS114066"],"award-info":[{"award-number":["R01NS114066"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["P41EB022544"],"award-info":[{"award-number":["P41EB022544"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["S10OD026987"],"award-info":[{"award-number":["S10OD026987"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]3F4AP is a novel PET radiotracer that targets voltage-gated potassium (K\n                      <jats:sup>+<\/jats:sup>\n                      ) channels and has shown promise for imaging demyelinated lesions in animal models of neurological diseases. This study aimed to evaluate the biodistribution, safety, and radiation dosimetry of [\n                      <jats:sup>18<\/jats:sup>\n                      F]3F4AP in healthy human volunteers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Four healthy volunteers (2 females) underwent a 4-h dynamic PET scan from the cranial vertex to mid-thigh using multiple bed positions after administration of 368\u2009\u00b1\u200917.9\u00a0MBq (9.94\u2009\u00b1\u20090.48\u00a0mCi) of [\n                      <jats:sup>18<\/jats:sup>\n                      F]3F4AP. Volumes of interest for relevant organs were manually drawn guided by the CT, and PET images and time-activity curves (TACs) were extracted. Radiation dosimetry was estimated from the integrated TACs using OLINDA software. Safety assessments included measuring vital signs immediately before and after the scan, monitoring for adverse events, and obtaining a comprehensive metabolic panel and electrocardiogram within 30\u00a0days before and after the scan.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]3F4AP distributed throughout the body with the highest levels of activity in the kidneys, urinary bladder, stomach, liver, spleen, and brain and with low accumulation in muscle and fat. The tracer cleared quickly from circulation and from most organs. The clearance of the tracer was noticeably faster than previously reported in nonhuman primates (NHPs). The average effective dose (ED) across all subjects was 12.1\u2009\u00b1\u20092.2 \u03bcSv\/MBq, which is lower than the estimated ED from the NHP studies (21.6\u2009\u00b1\u20090.6 \u03bcSv\/MBq) as well as the ED of other fluorine-18 radiotracers such as [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG (~\u200920 \u03bcSv\/MBq). No differences in ED between males and females were observed. No substantial changes in safety assessments or adverse events were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The biodistribution and radiation dosimetry of [\n                      <jats:sup>18<\/jats:sup>\n                      F]3F4AP in humans are reported for the first time. The average total ED across four subjects was lower than most\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled PET tracers. The tracer and study procedures were well tolerated, and no adverse events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-022-05980-w","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:02:41Z","timestamp":1664928161000},"page":"344-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-2743","authenticated-orcid":false,"given":"Pedro","family":"Brugarolas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses Q.","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Noel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia-Ann","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle R.","family":"Vesper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla M.","family":"Ramos-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas J.","family":"Guehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina T.","family":"Macdonald-Soccorso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Yokell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc D.","family":"Normandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"El Fakhri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"5980_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41598-017-18747-3","volume":"8","author":"P Brugarolas","year":"2018","unstructured":"Brugarolas P, Sanchez-Rodriguez JE, Tsai HM, Basuli F, Cheng SH, Zhang X, et al. Development of a PET radioligand for potassium channels to image CNS demyelination. Sci Rep. 2018;8:607. https:\/\/doi.org\/10.1038\/s41598-017-18747-3.","journal-title":"Sci Rep"},{"key":"5980_CR2","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1093\/brain\/awl144","volume":"129","author":"I Coman","year":"2006","unstructured":"Coman I, Aigrot MS, Seilhean D, Reynolds R, Girault JA, Zalc B, et al. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain. 2006;129:3186\u201395. https:\/\/doi.org\/10.1093\/brain\/awl144.","journal-title":"Brain"},{"key":"5980_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/cne.20321","volume":"479","author":"EJ Arroyo","year":"2004","unstructured":"Arroyo EJ, Sirkowski EE, Chitale R, Scherer SS. Acute demyelination disrupts the molecular organization of peripheral nervous system nodes. J Comparative Neurol. 2004;479:424\u201334. https:\/\/doi.org\/10.1002\/cne.20321.","journal-title":"J Comparative Neurol"},{"key":"5980_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1523\/JNEUROSCI.18-01-00036.1998","volume":"18","author":"MN Rasband","year":"1998","unstructured":"Rasband MN, Trimmer JS, Schwarz TL, Levinson SR, Ellisman MH, Schachner M, et al. Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci. 1998;18:36\u201347.","journal-title":"J Neurosci"},{"key":"5980_CR5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/283570a0","volume":"283","author":"RM Sherratt","year":"1980","unstructured":"Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature. 1980;283:570\u20132.","journal-title":"Nature"},{"key":"5980_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1113\/jphysiol.1981.sp013666","volume":"313","author":"H Bostock","year":"1981","unstructured":"Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol. 1981;313:301\u201315.","journal-title":"J Physiol"},{"key":"5980_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0022-510X(83)90145-4","volume":"60","author":"RE Jones","year":"1983","unstructured":"Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci. 1983;60:353\u201362.","journal-title":"J Neurol Sci"},{"key":"5980_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ana.410210113","volume":"21","author":"D Stefoski","year":"1987","unstructured":"Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1987;21:71\u20137. https:\/\/doi.org\/10.1002\/ana.410210113.","journal-title":"Ann Neurol"},{"key":"5980_CR9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(09)60442-6.","journal-title":"Lancet"},{"key":"5980_CR10","doi-asserted-by":"publisher","first-page":"153601211878547","DOI":"10.1177\/1536012118785471","volume":"17","author":"P Brugarolas","year":"2018","unstructured":"Brugarolas P, Reich DS, Popko B. Detecting demyelination by PET: the lesion as imaging target. Mol Imaging. 2018;17:1536012118785471. https:\/\/doi.org\/10.1177\/1536012118785471.","journal-title":"Mol Imaging"},{"key":"5980_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1177\/0271678X20963404","volume":"41","author":"NJ Guehl","year":"2021","unstructured":"Guehl NJ, Ramos-Torres KM, Linnman C, Moon SH, Dhaynaut M, Wilks MQ, et al. Evaluation of the potassium channel tracer [18F]3F4AP in rhesus macaques. J Cereb Blood Flow Metab. 2021;41:1721\u201333. https:\/\/doi.org\/10.1177\/0271678X20963404.","journal-title":"J Cereb Blood Flow Metab"},{"key":"5980_CR12","first-page":"1461","volume":"62","author":"K Ramos-Torres","year":"2021","unstructured":"Ramos-Torres K, Noel J, Vesper D, Rice P, Brugarolas P, Yokell D. cGMP production of [18F]3F4AP for human PET imaging. Society of Nuclear Medicine Annual Meeting Abstracts. 2021;62:1461.","journal-title":"Society of Nuclear Medicine Annual Meeting Abstracts"},{"key":"5980_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/jlcr.3560","volume":"61","author":"F Basuli","year":"2018","unstructured":"Basuli F, Zhang X, Brugarolas P, Reich DS, Swenson RE. An efficient new method for the synthesis of 3-[18F]fluoro-4-aminopyridine via Yamada-Curtius rearrangement. J Labelled Comp Radiopharm. 2018;61:112\u20137. https:\/\/doi.org\/10.1002\/jlcr.3560.","journal-title":"J Labelled Comp Radiopharm"},{"key":"5980_CR14","first-page":"1133","volume":"54","author":"T Collier","year":"2013","unstructured":"Collier T, Normandin M, El Fakhri G, Vasdev N. Automation of column-switching HPLC for analysis of radiopharmaceuticals and their metabolites in plasma. Soc Nucl Med Ann Meet Abs. 2013;54:1133.","journal-title":"Soc Nucl Med Ann Meet Abs"},{"key":"5980_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/s0969-8051(00)00125-6","volume":"27","author":"J Hilton","year":"2000","unstructured":"Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627\u201330. https:\/\/doi.org\/10.1016\/s0969-8051(00)00125-6.","journal-title":"Nucl Med Biol"},{"key":"5980_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/21556660.2013.833099","volume":"2","author":"A Caggiano","year":"2013","unstructured":"Caggiano A, Blight A. Identification of metabolites of dalfampridine (4-aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways. J Drug Assess. 2013;2:117\u201326. https:\/\/doi.org\/10.3109\/21556660.2013.833099.","journal-title":"J Drug Assess"},{"key":"5980_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12880-016-0143-y","volume":"16","author":"B Quinn","year":"2016","unstructured":"Quinn B, Dauer Z, Pandit-Taskar N, Schoder H, Dauer LT. Radiation dosimetry of 18F-FDG PET\/CT: incorporating exam-specific parameters in dose estimates. BMC Med Imaging. 2016;16:41. https:\/\/doi.org\/10.1186\/s12880-016-0143-y.","journal-title":"BMC Med Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05980-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T19:06:31Z","timestamp":1673204791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05980-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5980"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05980-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.21.22275275","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PB has a financial interest in the Fuzionaire Diagnostics and the University of Chicago. PB is a named inventor of patents related to [<sup>18<\/sup>F]3F4AP owned by the University of Chicago and licensed to the Fuzionaire Diagnostics. PB\u2019s interests were reviewed and are managed by the MGH and Mass General Brigham in accordance with their conflict of interest policies. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}